MaxCyte Regulatory News (MXCT)

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options, PDMR dealing and Total Voting Rights

ROCKVILLE, MD, February 6, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that between 1 February 2023 and 2 February 2023, as per filings lodged with the SEC, Doug Doerfler, Chief Executive Officer, exercised options over 30,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 30,000 new shares of Common Stock issued pursuant to the Exercise ("New Common Stock"), were sold by Doug Doerfler at a price range between of $5.50 and $5.885 per Common Stock ("Sale"). The sold shares represent approximately 0.9% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise, Doug Doerfler holds a further 2,953,680 options over Common Stock and still holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doerfler on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.

Total voting rights

The 30,000 New Common Stock have been admitted to trading on AIM pursuant to the Block Listing announced by the Company on September 6, 2021. The New Common Stock will rank pari passu with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the above will be 102,904,745 shares of common stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx®, STx® GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

Learn more at maxcyte.com and follow us on Twitter and LinkedIn.